The clinical success of the platinum-based chemotherapeutic agents has prompted the
investigation of coordination and organometallic complexes of alternative metal centers for …

Research in the field of bioinorganic chemistry has been stimulated by the worldwide
success of the anticancer drug cisplatin. 40 years after the first report about its biological …

Age-related change in human haematopoiesis causes reduced regenerative capacity,
cytopenias, immune dysfunction and increased risk of blood cancer,–, but the reason for …

In this manuscript we focus on Pt (IV) anticancer prodrugs. We explore the main working
hypotheses for the design of effective Pt (IV) prodrugs and note the exceptions to the …

The antitumor activity of the organometallic ruthenium (II)− arene complexes, RuCl2 (η6-
arene)(PTA),(arene= p-cymene, toluene, benzene, benzo-15-crown-5, 1-ethylbenzene-2, 3 …

Since the introduction of platinum-based combination chemotherapy, particularly cisplatin,
the outcome of the treatment of many solid tumours has changed. The leading platinum …

Platinum (IV) pro-drugs are an important class of molecules that might improve the
pharmacological properties of the platinum (II) anticancer agents that are currently used in …

The mortality rates from various tumor types can be reduced dramatically by use of highly
active drugs. This is particularly true for platinum-based drugs, being among the most …

The history of platinum in cancer treatment began 150 years ago with the first synthesis of
cisplatin; but it was not used in the clinic before 30 years ago. Then 3000 derivatives were …

25 years after the first approval of cisplatin in the clinic against a number of cancer diseases,
cisplatin and related compounds continue to be among the most efficient anticancer drugs …